Steven Pfanstiel Sells 16,431 Shares of Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) EVP Steven Pfanstiel sold 16,431 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $1.34, for a total transaction of $22,017.54. Following the sale, the executive vice president owned 828,781 shares of the company’s stock, valued at $1,110,566.54. This trade represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Neuronetics Trading Down 5.0%

Neuronetics stock opened at $1.33 on Friday. Neuronetics, Inc. has a 52 week low of $0.80 and a 52 week high of $4.85. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02. The firm has a market capitalization of $92.14 million, a PE ratio of -2.25 and a beta of 0.87. The business’s 50-day simple moving average is $1.56 and its 200-day simple moving average is $1.98.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, March 17th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.02. The firm had revenue of $41.78 million during the quarter, compared to the consensus estimate of $40.84 million. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%. Equities research analysts forecast that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Institutional Trading of Neuronetics

Several institutional investors have recently made changes to their positions in the business. Presidio Capital Management LLC acquired a new position in Neuronetics in the third quarter worth about $32,000. Intrua Financial LLC acquired a new stake in Neuronetics during the third quarter valued at approximately $33,000. Sherbrooke Park Advisers LLC acquired a new stake in Neuronetics during the third quarter valued at approximately $33,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Neuronetics in the 2nd quarter valued at approximately $34,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Neuronetics in the 2nd quarter valued at approximately $37,000. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on STIM shares. Wall Street Zen downgraded shares of Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group decreased their price target on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.00.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.